Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 14, 2026, titled "Zydus receives final approval from USFDA for Ammonium Lactate Cream, 12%".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has received final approval from the USFDA to market Ammonium Lactate Cream, 12% in the United States. Ammonium Lactate Cream is commonly used to treat dry, scaly skin conditions. The approval allows the company to launch and sell this product in the US market through its generic portfolio. This adds another product to Zydus's growing US formulations pipeline. Specific revenue expectations or market size details were not disclosed in the announcement.
This approval strengthens Zydus's US generic portfolio and could support incremental revenue from the US business, though no financial guidance was provided. Near-term stock impact may be modest unless market potential is significant.